We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Perrigo (PRGO - Free Report) reported adjusted earnings of 60 cents per share in the first quarter of 2025, beating the Zacks Consensus Estimate of 56 cents. The reported figure increased 107% year over year, primarily driven by improved margins and lower variable expenses.
Net sales declined 3.5% year over year to $1.04 billion, missing the Zacks Consensus Estimate of $1.08 billion. The downside was due to the loss of sales stemming from exited businesses and product lines, and unfavorable currency movements.
During the quarter, sales dropped 2% year over year on account of exited businesses and product lines and another 1.2% from unfavorable currency movement. At constant currency (excluding foreign currency translation), sales fell 2.4%. Organic net sales (excluding the effects of acquisitions and divestitures and the impact of currency) declined 0.4%.
More on PRGO’s Earnings
Perrigo reports its results under the following segments: Consumer Self Care Americas (CSCA) and Consumer Self Care International (CSCI).
CSCA: The segment’s net sales in the quarter came in at $621 million, down 3.6% year over year. Though sales grew across the Nutrition and Upper Respiratory categories, they were more than offset by lost distribution in U.S. Store Brand, a tough comparison in Women's Health following last year’s Opill launch, and lower sales in the Digestive Health category. Organic net sales also declined 3.6%. The reported segment sales missed the Zacks Consensus Estimate of $657 million and our model estimate of $638 million.
CSCI: The segment reported net sales of $423 million, down 3.4% from the year-ago period’s levels due to unfavorable impact from divested businesses, exited product lines and currency translation. At constant currency rates, sales were down 0.6% year over year. Organically, sales increased 4.5%. CSCI sales missed both the Zacks Consensus Estimate and our model estimate of $432 million and $434 million, respectively.
PRGO’s 2025 Guidance
Perrigo widened its full-year sales outlook due to macroeconomic uncertainty, including the potential impact of new tariffs. It now expects total net sales growth in the range of 0-3% year over year, compared to the prior guidance of 1-3%.
While PRGO expects tariffs to raise costs, especially in its Oral Care segment that relies heavily on Chinese sourcing, it believes the impact will be manageable. With 85% of its finished goods produced in the United States, the company plans to offset most of the pressure through price adjustments, shifting production to domestic facilities and other supply chain strategies. These reassurances likely contributed to the 5% rise in Perrigo shares during premarket trading.
Year to date, shares of Perrigo have lost 4% against the industry’s 4% growth.
Image Source: Zacks Investment Research
Despite the revision in the top line, Perrigo reiterated all other 2025 financial targets, including an adjusted EPS range of $2.90 to $3.10, an adjusted gross margin of around 40%, and adjusted operating margins near 15%.
Estimates for Puma Biotechnology’s 2025 EPS have increased from 52 cents to 54 cents over the past 60 days, while the same for 2026 has increased from 49 cents to 54 cents.
Puma’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 88.62%. Year to date, PBYI stock is down 2%.
In the past 60 days, estimates for Elevation Oncology’s 2025 loss per share have narrowed from 83 cents to 61 cents. Loss per share estimates for 2026 have narrowed from 88 cents to 44 cents during the same time. Year to date, shares of ELEV have declined 40%.
ELEV’s earnings beat estimates in two of the trailing four quarters while missing on the remaining occasions, the average surprise being 5.10%.
In the past 60 days, estimates for Intellia Therapeutics’ 2025 loss per share have improved from $4.75 to $4.62. During the same timeframe, estimates for 2026 loss per share have narrowed from $4.68 to $4.62.
Intellia’s earnings beat estimates in three of the trailing four quarters and missed the mark once, delivering an average surprise of 5.37%. The stock has lost 38% year to date.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Perrigo Q1 Earnings Beat Estimates, Revenues Decline Y/Y
Perrigo (PRGO - Free Report) reported adjusted earnings of 60 cents per share in the first quarter of 2025, beating the Zacks Consensus Estimate of 56 cents. The reported figure increased 107% year over year, primarily driven by improved margins and lower variable expenses.
Net sales declined 3.5% year over year to $1.04 billion, missing the Zacks Consensus Estimate of $1.08 billion. The downside was due to the loss of sales stemming from exited businesses and product lines, and unfavorable currency movements.
During the quarter, sales dropped 2% year over year on account of exited businesses and product lines and another 1.2% from unfavorable currency movement. At constant currency (excluding foreign currency translation), sales fell 2.4%. Organic net sales (excluding the effects of acquisitions and divestitures and the impact of currency) declined 0.4%.
More on PRGO’s Earnings
Perrigo reports its results under the following segments: Consumer Self Care Americas (CSCA) and Consumer Self Care International (CSCI).
CSCA: The segment’s net sales in the quarter came in at $621 million, down 3.6% year over year. Though sales grew across the Nutrition and Upper Respiratory categories, they were more than offset by lost distribution in U.S. Store Brand, a tough comparison in Women's Health following last year’s Opill launch, and lower sales in the Digestive Health category. Organic net sales also declined 3.6%. The reported segment sales missed the Zacks Consensus Estimate of $657 million and our model estimate of $638 million.
CSCI: The segment reported net sales of $423 million, down 3.4% from the year-ago period’s levels due to unfavorable impact from divested businesses, exited product lines and currency translation. At constant currency rates, sales were down 0.6% year over year. Organically, sales increased 4.5%. CSCI sales missed both the Zacks Consensus Estimate and our model estimate of $432 million and $434 million, respectively.
PRGO’s 2025 Guidance
Perrigo widened its full-year sales outlook due to macroeconomic uncertainty, including the potential impact of new tariffs. It now expects total net sales growth in the range of 0-3% year over year, compared to the prior guidance of 1-3%.
While PRGO expects tariffs to raise costs, especially in its Oral Care segment that relies heavily on Chinese sourcing, it believes the impact will be manageable. With 85% of its finished goods produced in the United States, the company plans to offset most of the pressure through price adjustments, shifting production to domestic facilities and other supply chain strategies. These reassurances likely contributed to the 5% rise in Perrigo shares during premarket trading.
Year to date, shares of Perrigo have lost 4% against the industry’s 4% growth.
Image Source: Zacks Investment Research
Despite the revision in the top line, Perrigo reiterated all other 2025 financial targets, including an adjusted EPS range of $2.90 to $3.10, an adjusted gross margin of around 40%, and adjusted operating margins near 15%.
PRGO’s Zacks Rank
Perrigo currently has a Zacks Rank #3 (Hold).
Perrigo Company plc Price
Perrigo Company plc price | Perrigo Company plc Quote
Our Key Picks Among Biotech Stocks
Some better-ranked stocks from the industry are Puma Biotechnology (PBYI - Free Report) , Elevation Oncology (ELEV - Free Report) and Intellia Therapeutics (NTLA - Free Report) . While PBYI sports a Zacks Rank #1 (Strong Buy) at present, ELEV and NTLA carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for Puma Biotechnology’s 2025 EPS have increased from 52 cents to 54 cents over the past 60 days, while the same for 2026 has increased from 49 cents to 54 cents.
Puma’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 88.62%. Year to date, PBYI stock is down 2%.
In the past 60 days, estimates for Elevation Oncology’s 2025 loss per share have narrowed from 83 cents to 61 cents. Loss per share estimates for 2026 have narrowed from 88 cents to 44 cents during the same time. Year to date, shares of ELEV have declined 40%.
ELEV’s earnings beat estimates in two of the trailing four quarters while missing on the remaining occasions, the average surprise being 5.10%.
In the past 60 days, estimates for Intellia Therapeutics’ 2025 loss per share have improved from $4.75 to $4.62. During the same timeframe, estimates for 2026 loss per share have narrowed from $4.68 to $4.62.
Intellia’s earnings beat estimates in three of the trailing four quarters and missed the mark once, delivering an average surprise of 5.37%. The stock has lost 38% year to date.